NCT01332279 2023-04-04
Everolimus, Erlotinib Hydrochloride, and Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer Previously Treated With Radiation Therapy
Fox Chase Cancer Center
Phase 1 Withdrawn
Clinical Trials
13 trialsNCT05079360 2023-03-24
Efficacy Evaluation of Sabizabulin Monotherapy Versus Active Control for Treatment of ER+HER2- Metastatic Breast Cancer
Veru Inc.
Phase 2 Withdrawn
NCT02860494 2021-05-03
EVEROST
Hospices Civils de Lyon
Phase 2/3 Withdrawn
NCT03632317 2019-08-19
A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas
University of Michigan Rogel Cancer Center
Phase 2 Withdrawn
NCT00855114 2017-12-02
Everolimus in Treating Women With Breast Cancer That Can Be Removed by Surgery
Masonic Cancer Center, University of Minnesota
Phase 2 Withdrawn
NCT01997255 2016-05-05
Adjunctive Everolimus (RAD 001) Therapy for Epilepsy in Children With Sturge-Weber Syndrome (SWS)
Baylor College of Medicine
Phase 2 Withdrawn
NCT01188889 2015-05-15
RAD001 in Patients With Chronic Phase Chronic Myeloid Leukemia w/ Molecular Disease.
University of Michigan Rogel Cancer Center
Phase 1/2 Withdrawn
NCT01178151 2015-04-22
EVAMP
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Phase 2 Withdrawn
NCT01864070 2014-07-22
Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease
M.D. Anderson Cancer Center
Phase 1 Withdrawn
NCT00967928 2014-02-14
Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
Accelerated Community Oncology Research Network
Phase 1 Withdrawn
NCT01616186 2013-04-08
Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC)
University of California, San Francisco
Phase 2 Withdrawn
NCT01234974 2013-01-10
IGF-1 Inhibitor Pasireotide Lar in Combination With the m-TOR Inhibitor Everolimus
Milton S. Hershey Medical Center
Phase 2 Withdrawn
NCT01163929 2012-10-24
A Study to Look at the Combination of Chemotherapy, Trastuzumab and RAD001 in HER2 Positive Breast Cancer
University of Kansas Medical Center
Phase 2 Withdrawn